Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | F13A1 | P00488 | 2/20 | 0.58 |
| ▸ | TGM1 | P22735 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31284709 | 0.98 | KMT2A (0.68) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| SCHEMBL29571128 | 0.95 | KMT2A (0.68) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| SCHEMBL27006685 | 0.95 | KMT2A (0.68) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| SCHEMBL25166782 | 0.94 | ALDH1A1 (0.60) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| SCHEMBL7007500 | 0.94 | ALDH1A1 (0.60) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| SCHEMBL7898705 | 0.94 | ALDH1A1 (0.60) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| Hydrochloric Acid SCHEMBL6792141 | 0.93 | SCN1A (0.61) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| SCHEMBL14572312 | 0.93 | RECQL (0.62) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| SCHEMBL14572299 | 0.93 | RECQL (0.62) | KMT2AMEN1NPY5RALDH1A1CYP19A1 | |
| SCHEMBL25682870 | 0.93 | RECQL (0.62) | KMT2AMEN1NPY5RALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095031-B1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2013-08-21 | — | — | EP | disclosed |
| US-7709486-B2 | antiviral compounds 1,4,8,11-tetraazacyclotetradecane derivatives for against HIV-infected cells, to inhibit the binding by the natural ligand to its chemokine receptor; viricides | GENZYME CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080287454-A1 | CXCR4 ANTAGONISTS | BRIDGER GARY J | 2008-11-20 | — | — | US | disclosed |
| US-7414065-B2 | Methods to modulate conditions mediated by the CXCR4 receptor | GENZYME CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-7160872-B2 | Methods to treat conditions mediated by chemokine receptors | ANORMED INC. (CA) | 2007-01-09 | — | — | US | disclosed |
| US-20050154005-A1 | Methods to modulate conditions mediated by the CXCR4 receptor | GENZYME CORPORATION | 2005-07-14 | — | — | US | disclosed |
| US-6872714-B1 | Methods to modulate conditions mediated by the CXCR4 receptor | ANORMED INC. (CA) | 2005-03-29 | — | — | US | disclosed |
| US-20040235814-A1 | Methods to treat conditions mediated by chemokine receptors | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6756391-B2 | CYCLIC POLYAMINES HAVING TOTAL 9-24 MEMBERS WHICH HAVE ACTIVITY IN AGAINST HIV-INFECTED CELLS AS WELL AS OTHER BIOLOGICAL ACTIVITY RELATED TO BINDING OF LIGANDS TO CHEMOKINE RECEPTORS | ANORMED, INC. (CA) | 2004-06-29 | — | — | US | disclosed |
| US-20030018189-A1 | Cyclic polyamines having total 9-24 members which have activity in against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6506770-B1 | Drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV-infected cells as well | ANORMED, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1095031-A1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002870-A1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | KMT2A 2209/4885MEN1 3670/4885NPY5R 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.